Naval Facilities Engineering Command (NAVFAC) awarded 5 companies firm-fixed price, indefinite-delivery/ indefinite-quantity contracts for assessment, repair, and construction of petroleum, oils and lubricant (POL) fuel systems at various U.S. Department of Defense (DoD) locations worldwide.
The value for all the contracts combined is $70 million. The contracts also include unexercised options, which if exercised would increase their cumulative value to $350 million.
DID has more on the winning companies and the contract numbers…
Alliant Techsystems in Minneapolis, MN received a firm-fixed-price contract with a maximum value of $7.6 million to supply M1028 120mm canister catridges to the U.S. Army. The contract has a base year and 4 one-year options.
The U.S. Army Joint Munitions & Lethality Life Cycle Management Command (JM&L LCMC) manages the contract (W15QKN-08-C-0473).
The M1028 is a tank fired, anti-personnel canister cartridge intended to be used against advancing dismounted infantry armed with hand held anti-tank and automatic weapons at close range.
The cartridge is to be fired from the M1A1/M1A2 Abrams main battle tank with the M256 smoothbore cannon.
DID has more on the M1028 as well as the Army facilities that Alliant will be supplying…
Taos Industries in Huntsville, AL, received 2 task orders worth $8.5 million for the operation of 6 Defense Reutilization and Marketing Offices (DRMOs) in Kuwait, Iraq and Afghanistan. The DRMOs demilitarize and dispose of excess and unserviceable military property, with the exceptions of ordnance and HAZMAT, for U.S. military and allied forces.
Taos, a subsidiary of Agility Defense & Government Services, won the original 5-year, $97.7 million firm-fixed-price contract (SP4410-08-D-2000) in November 2007. The contract is managed by Defense Reutilization and Marketing Service (DRMS), a unit of the Defense Logistics Agency, based in Battle Creek, MI.
PolyMedix of Radnor, PA has now received 3 biodefense-related contracts from the US government, including a a $1.6 million, 1-year contract from the US Defense Threat Reduction Agency (DTRA) to develop new “defensin-mimetic antibiotic compounds.” The primary goal of that contract is to devise more effective rapid-response countermeasures against anthrax, plague, and tularemia. Other work may have benefits against pan-Staphylococcal infections, and pneumonia.
How does their proposed approach work, and what makes it novel?